{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:46:25Z","timestamp":1792813585925,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Special Project for Clinical and Basic Sci&Tech Innovation of Guangdong Medical University","award":["GDMULCJC2024134"],"award-info":[{"award-number":["GDMULCJC2024134"]}]},{"name":"Foshan Antitumor Innovative Drug Research and Engineering Technology Center","award":["FS0AA-KJ819-4901-0082"],"award-info":[{"award-number":["FS0AA-KJ819-4901-0082"]}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1515130009"],"award-info":[{"award-number":["2023B1515130009"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573331"],"award-info":[{"award-number":["82573331"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10495-025-02199-6","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:10:07Z","timestamp":1768036207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiotoxicity induced by traditional chemotherapy: mechanisms and mitigation strategies"],"prefix":"10.1007","volume":"31","author":[{"given":"Jiahui","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2013.07.006","volume":"89","author":"S Puyo","year":"2014","unstructured":"Puyo S, Montaudon D, Pourquier P (2014) From old alkylating agents to new minor groove binders. Crit Rev Oncol Hematol 89:43\u201361. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF et al (2024) Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi 46:221\u2013231. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240119-00035","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1042\/CS20190653","volume":"134","author":"K Dadson","year":"2020","unstructured":"Dadson K, Calvillo-Arg\u00fcelles O, Thavendiranathan P, Billia F (2020) Anthracycline-induced cardiomyopathy: cellular and molecular mechanisms. Clin Sci (Lond) 134:1859\u20131885. https:\/\/doi.org\/10.1042\/CS20190653","journal-title":"Clin Sci (Lond)"},{"key":"2199_CR4","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ETH Yeh","year":"2009","unstructured":"Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231\u20132247. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.050","journal-title":"J Am Coll Cardiol"},{"key":"2199_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL (2020) Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol 33:125\u2013136. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387","journal-title":"Chem Res Toxicol"},{"key":"2199_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10741-020-09968-2","volume":"26","author":"Y Saleh","year":"2021","unstructured":"Saleh Y, Abdelkarim O, Herzallah K, Abela GS (2021) Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev 26:1159\u20131173. https:\/\/doi.org\/10.1007\/s10741-020-09968-2","journal-title":"Heart Fail Rev"},{"issue":"Suppl 1","key":"2199_CR7","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","volume":"213","author":"D Pantazi","year":"2022","unstructured":"Pantazi D, Tselepis AD (2022) Cardiovascular toxic effects of antitumor agents: pathogenetic mechanisms. Thromb Res 213(Suppl 1):S95\u2013S102. https:\/\/doi.org\/10.1016\/j.thromres.2021.12.017","journal-title":"Thromb Res"},{"key":"2199_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2018.01.002","volume":"1869","author":"I Marques-Aleixo","year":"2018","unstructured":"Marques-Aleixo I, Santos-Alves E, Oliveira PJ et al (2018) The beneficial role of exercise in mitigating doxorubicin-induced mitochondrionopathy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1869:189\u2013199. https:\/\/doi.org\/10.1016\/j.bbcan.2018.01.002","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"2199_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4965171","volume":"2020","author":"MA Ayza","year":"2020","unstructured":"Ayza MA, Zewdie KA, Tesfaye BA et al (2020) The role of antioxidants in ameliorating cyclophosphamide-induced cardiotoxicity. Oxid Med Cell Longev 2020:1\u201314. https:\/\/doi.org\/10.1155\/2020\/4965171","journal-title":"Oxid Med Cell Longev"},{"key":"2199_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005443","volume":"10","author":"V Buza","year":"2017","unstructured":"Buza V, Rajagopalan B, Curtis AB (2017) Cancer treatment\u2013induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol 10:e005443. https:\/\/doi.org\/10.1161\/CIRCEP.117.005443","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2199_CR11","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/c8dt00838h","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 47:6645\u20136653. https:\/\/doi.org\/10.1039\/c8dt00838h","journal-title":"Dalton Trans"},{"key":"2199_CR12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0762","volume":"25","author":"I Raber","year":"2020","unstructured":"Raber I, Warack S, Kanduri J et al (2020) Fluoropyrimidine-associated cardiotoxicity: a retrospective case-control study. Oncologist 25:e606. https:\/\/doi.org\/10.1634\/theoncologist.2019-0762","journal-title":"Oncologist"},{"key":"2199_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K et al (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther 206:107447. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447","journal-title":"Pharmacol Ther"},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cjca.2016.01.027","volume":"32","author":"R Moudgil","year":"2016","unstructured":"Moudgil R, Yeh ETH (2016) Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol 32:863\u2013870. https:\/\/doi.org\/10.1016\/j.cjca.2016.01.027","journal-title":"Can J Cardiol"},{"key":"2199_CR15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/bcp.13895","volume":"85","author":"R Iacovelli","year":"2019","unstructured":"Iacovelli R, Ciccarese C, Fornarini G et al (2019) Cabozantinib-related cardiotoxicity: a prospective analysis in a real\u2010world cohort of metastatic renal cell carcinoma patients. Br J Clin Pharmacol 85:1283\u20131289. https:\/\/doi.org\/10.1111\/bcp.13895","journal-title":"Br J Clin Pharmacol"},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1093\/oncolo\/oyab035","volume":"27","author":"C Lestuzzi","year":"2022","unstructured":"Lestuzzi C, Stolfo D, De Paoli A et al (2022) Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise. Oncologist 27:e158\u2013e167. https:\/\/doi.org\/10.1093\/oncolo\/oyab035","journal-title":"Oncologist"},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00392-016-1011-z","volume":"105","author":"F Escher","year":"2016","unstructured":"Escher F, K\u00fchl U, Lassner D et al (2016) Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 105:1011\u20131020. https:\/\/doi.org\/10.1007\/s00392-016-1011-z","journal-title":"Clin Res Cardiol"},{"key":"2199_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004228","volume":"11","author":"J Merken","year":"2018","unstructured":"Merken J, Hazebroek M, Van Paassen P et al (2018) Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail 11:e004228. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004228","journal-title":"Circ Heart Fail"},{"key":"2199_CR19","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1093\/eurheartj\/ehac348","volume":"43","author":"C Chimenti","year":"2022","unstructured":"Chimenti C, Russo MA, Frustaci A (2022) Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J 43:3463\u20133473. https:\/\/doi.org\/10.1093\/eurheartj\/ehac348","journal-title":"Eur Heart J"},{"key":"2199_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biology12030356","volume":"12","author":"J Grzechoci\u0144ska","year":"2023","unstructured":"Grzechoci\u0144ska J, Tymi\u0144ska A, Giordani AS et al (2023) Immunosuppressive therapy of biopsy-proven, virus-negative, autoimmune\/immune-mediated myocarditis-focus on azathioprine: a review of existing evidence and future perspectives. Biology 12:356. https:\/\/doi.org\/10.3390\/biology12030356","journal-title":"Biology"},{"key":"2199_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13256-022-03644-9","volume":"16","author":"S Shah","year":"2022","unstructured":"Shah S, Haeger-Overstreet K, Flynn B (2022) Methotrexate-induced acute cardiotoxicity requiring veno-arterial extracorporeal membrane oxygenation support: a case report. J Med Case Rep 16:447. https:\/\/doi.org\/10.1186\/s13256-022-03644-9","journal-title":"J Med Case Rep"},{"key":"2199_CR22","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.26355\/eurrev_202110_26879","volume":"25","author":"RH Mahmoud","year":"2021","unstructured":"Mahmoud RH, Mohammed MA, Said ES et al (2021) Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats. Eur Rev Med Pharmacol Sci 25:6013\u20136024. https:\/\/doi.org\/10.26355\/eurrev_202110_26879","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2199_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1023\/a:1008380208045","volume":"11","author":"D Santini","year":"2000","unstructured":"Santini D, Tonini G, Abbate A et al (2000) Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol 11:479\u2013481. https:\/\/doi.org\/10.1023\/a:1008380208045","journal-title":"Ann Oncol"},{"key":"2199_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ehf2.12113","volume":"4","author":"D Mohebali","year":"2017","unstructured":"Mohebali D, Matos J, Chang JD (2017) Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity. ESC Heart Fail 4:71\u201374. https:\/\/doi.org\/10.1002\/ehf2.12113","journal-title":"ESC Heart Fail"},{"key":"2199_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 17:474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1","journal-title":"Nat Rev Cardiol"},{"key":"2199_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106951","volume":"121","author":"S-I Fujiwara","year":"2022","unstructured":"Fujiwara S-I, Murahashi R, Nakashima H et al (2022) Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation. Leuk Res 121:106951. https:\/\/doi.org\/10.1016\/j.leukres.2022.106951","journal-title":"Leuk Res"},{"key":"2199_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11912-019-0751-0","volume":"21","author":"N Shelburne","year":"2019","unstructured":"Shelburne N, Simonds NI, Adhikari B et al (2019) Changing hearts and minds: improving outcomes in cancer treatment-related cardiotoxicity. Curr Oncol Rep 21:9. https:\/\/doi.org\/10.1007\/s11912-019-0751-0","journal-title":"Curr Oncol Rep"},{"key":"2199_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front Cardiovasc Med 7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026","journal-title":"Front Cardiovasc Med"},{"key":"2199_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/4938287","volume":"2023","author":"Z Ping","year":"2023","unstructured":"Ping Z, Fangfang T, Yuliang Z et al (2023) Oxidative stress and pyroptosis in Doxorubicin-induced heart failure and atrial fibrillation. Oxid Med Cell Longev 2023:1\u20138. https:\/\/doi.org\/10.1155\/2023\/4938287","journal-title":"Oxid Med Cell Longev"},{"key":"2199_CR30","doi-asserted-by":"publisher","first-page":"732554","DOI":"10.3389\/fcvm.2021.732554","volume":"8","author":"W Yun","year":"2021","unstructured":"Yun W, Qian L, Yuan R, Xu H (2021) Periplocymarin alleviates Doxorubicin-induced heart failure and excessive accumulation of ceramides. Front Cardiovasc Med 8:732554. https:\/\/doi.org\/10.3389\/fcvm.2021.732554","journal-title":"Front Cardiovasc Med"},{"key":"2199_CR31","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/j.clml.2021.06.002","volume":"21","author":"R Mi","year":"2021","unstructured":"Mi R, Zhao J, Chen L et al (2021) Efficacy and safety of Homoharringtonine for the treatment of acute myeloid leukemia: a meta-analysis. Clin Lymphoma Myeloma Leuk 21:e752\u2013e767. https:\/\/doi.org\/10.1016\/j.clml.2021.06.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2199_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/br.2018.1158","author":"D Zhao","year":"2018","unstructured":"Zhao D, Chen J, Liu X et al (2018) Atrial fibrillation following treatment with paclitaxel: a case report. Biom Rep. https:\/\/doi.org\/10.3892\/br.2018.1158","journal-title":"Biom Rep"},{"key":"2199_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM (1986) Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68:1114\u20131118","journal-title":"Blood"},{"key":"2199_CR34","doi-asserted-by":"crossref","unstructured":"Iqubal A, Iqubal MK, Sharma S et al (2019) Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. Life Sci. 218:112\u2013131","DOI":"10.1016\/j.lfs.2018.12.018"},{"key":"2199_CR35","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","volume":"9","author":"AC Braverman","year":"1991","unstructured":"Braverman AC, Antin JH, Plappert MT et al (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215\u20131223. https:\/\/doi.org\/10.1200\/JCO.1991.9.7.1215","journal-title":"J Clin Oncol"},{"key":"2199_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jccase.2019.05.001","volume":"20","author":"G Newbery","year":"2019","unstructured":"Newbery G, Lima NDA, Gurgel LA et al (2019) Persistent heart failure following melphalan and fludarabine conditioning. J Cardiol Cases 20:88\u201391. https:\/\/doi.org\/10.1016\/j.jccase.2019.05.001","journal-title":"J Cardiol Cases"},{"key":"2199_CR37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/clc.20904","volume":"34","author":"V Feliz","year":"2011","unstructured":"Feliz V, Saiyad S, Ramarao SM et al (2011) Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 34:356\u2013359. https:\/\/doi.org\/10.1002\/clc.20904","journal-title":"Clin Cardiol"},{"key":"2199_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/biom12030463","volume":"12","author":"J Xu","year":"2022","unstructured":"Xu J, Gewirtz DA (2022) Is autophagy always a barrier to cisplatin therapy? Biomolecules 12:463. https:\/\/doi.org\/10.3390\/biom12030463","journal-title":"Biomolecules"},{"key":"2199_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/a-0649-4878","volume":"52","author":"M Brinkmann","year":"2021","unstructured":"Brinkmann M, Tallone EM, W\u00fcrschmidt F et al (2021) Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin. Aktuelle Urol 52:54\u201357. https:\/\/doi.org\/10.1055\/a-0649-4878","journal-title":"Aktuelle Urol"},{"key":"2199_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-019-0048-3","volume":"5","author":"C Yuan","year":"2019","unstructured":"Yuan C, Parekh H, Allegra C et al (2019) 5-FU induced cardiotoxicity: case series and review of the literature. Cardio Oncol 5:13. https:\/\/doi.org\/10.1186\/s40959-019-0048-3","journal-title":"Cardio-Oncology"},{"key":"2199_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/106002809402800314","volume":"28","author":"AJ Anand","year":"1994","unstructured":"Anand AJ (1994) Fluorouracil cardiotoxicity. Ann Pharmacother 28:374\u2013378. https:\/\/doi.org\/10.1177\/106002809402800314","journal-title":"Ann Pharmacother"},{"key":"2199_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P et al (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134:75\u201382. https:\/\/doi.org\/10.1007\/s00432-007-0250-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"2199_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang S-S, Huang H et al (2021) Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325:50. https:\/\/doi.org\/10.1001\/jama.2020.23370","journal-title":"JAMA"},{"key":"2199_CR44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bbagen.2016.12.014","volume":"1861","author":"M Sramek","year":"2017","unstructured":"Sramek M, Neradil J, Veselska R (2017) Much more than you expected: the non-DHFR-mediated effects of methotrexate. Biochim Biophys Acta Gen Subj 1861:499\u2013503. https:\/\/doi.org\/10.1016\/j.bbagen.2016.12.014","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2199_CR45","first-page":"S7-2","volume":"24","author":"AM Storniolo","year":"1997","unstructured":"Storniolo AM, Allerheiligen SR, Pearce HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:S7-2-S7-7","journal-title":"Semin Oncol"},{"key":"2199_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, Talpur R, Wen S et al (2006) Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7:51\u201358. https:\/\/doi.org\/10.3816\/CLM.2006.n.039","journal-title":"Clin Lymphoma Myeloma"},{"key":"2199_CR47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.bulcan.2020.04.010","volume":"107","author":"A Lambert","year":"2020","unstructured":"Lambert A, Salleron J, Kieffer A et al (2020) Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: series of 46 cases and comprehensive literature review. Bull Cancer 107:756\u2013762. https:\/\/doi.org\/10.1016\/j.bulcan.2020.04.010","journal-title":"Bull Cancer"},{"key":"2199_CR48","doi-asserted-by":"publisher","first-page":"e065075","DOI":"10.1136\/bmjopen-2022-065075","volume":"13","author":"DWL Ng","year":"2023","unstructured":"Ng DWL, Fielding R, Tsang C et al (2023) Study protocol of ConquerFear-HK: a randomised controlled trial of a metacognition-based, manualised intervention for fear of cancer recurrence among Chinese cancer survivors. BMJ Open 13:e065075. https:\/\/doi.org\/10.1136\/bmjopen-2022-065075","journal-title":"BMJ Open"},{"key":"2199_CR49","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2133.2006.07474.x","volume":"155","author":"T Yamamoto","year":"2006","unstructured":"Yamamoto T (2006) Bleomycin and the skin: bleomycin and the skin. Br J Dermatol 155:869\u2013875. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07474.x","journal-title":"Br J Dermatol"},{"key":"2199_CR50","doi-asserted-by":"publisher","unstructured":"Bassil E, Singh H, Ahmed O, Parikh S (2023) Case of ST-Elevation myocardial infarction in a 32-year-old male receiving bleomycin, etoposide, and cisplatin chemotherapy for embryonal carcinoma. Cureus. https:\/\/doi.org\/10.7759\/cureus.40089","DOI":"10.7759\/cureus.40089"},{"key":"2199_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.7150\/ijbs.44907","volume":"17","author":"L Wang","year":"2021","unstructured":"Wang L, Wang D, Wu L et al (2021) Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p\/AKT\/mTOR signaling pathway. Int J Biol Sci 17:995\u20131009. https:\/\/doi.org\/10.7150\/ijbs.44907","journal-title":"Int J Biol Sci"},{"key":"2199_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","volume":"24","author":"L Zhu","year":"2019","unstructured":"Zhu L, Chen L (2019) Progress in research on Paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 24:40. https:\/\/doi.org\/10.1186\/s11658-019-0164-y","journal-title":"Cell Mol Biol Lett"},{"key":"2199_CR53","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","volume":"22","author":"P Dhyani","year":"2022","unstructured":"Dhyani P, Quispe C, Sharma E et al (2022) Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, Vinorelbine and Vincamine. Cancer Cell Int 22:206. https:\/\/doi.org\/10.1186\/s12935-022-02624-9","journal-title":"Cancer Cell Int"},{"key":"2199_CR54","first-page":"1231","volume":"4","author":"M Moudi","year":"2013","unstructured":"Moudi M, Go R, Yien CYS, Nazre M (2013) Vinca alkaloids. Int J Prev Med 4:1231\u20131235","journal-title":"Int J Prev Med"},{"key":"2199_CR55","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1517\/14740338.2011.581660","volume":"10","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK (2011) Vinflunine: drug safety evaluation of this novel synthetic Vinca alkaloid. Expert Opin Drug Saf 10:645\u2013653. https:\/\/doi.org\/10.1517\/14740338.2011.581660","journal-title":"Expert Opin Drug Saf"},{"key":"2199_CR56","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2174\/138945012802009017","volume":"13","author":"A Capasso","year":"2012","unstructured":"Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13:1065\u20131071. https:\/\/doi.org\/10.2174\/138945012802009017","journal-title":"Curr Drug Targets"},{"key":"2199_CR57","doi-asserted-by":"publisher","first-page":"e001849","DOI":"10.1136\/openhrt-2021-001849","volume":"8","author":"A Batra","year":"2021","unstructured":"Batra A, Patel B, Addison D et al (2021) Cardiovascular safety profile of taxanes and Vinca alkaloids: 30 years FDA registry experience. Open Heart 8:e001849. https:\/\/doi.org\/10.1136\/openhrt-2021-001849","journal-title":"Open Heart"},{"key":"2199_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F et al (2021) Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat 54:100742. https:\/\/doi.org\/10.1016\/j.drup.2020.100742","journal-title":"Drug Resist Updat"},{"key":"2199_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1025018","volume":"13","author":"C Wu","year":"2022","unstructured":"Wu C, Wu T, Chen D et al (2022) The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: a review of current evidence. Front Endocrinol (Lausanne) 13:1025018. https:\/\/doi.org\/10.3389\/fendo.2022.1025018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2199_CR60","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR et al (2013) Assessment of Dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia. long-term follow-up of a prospective, randomised, multicentre trial"},{"key":"2199_CR61","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. JCO 25:3808\u20133815. https:\/\/doi.org\/10.1200\/JCO.2006.10.4976","journal-title":"JCO"},{"key":"2199_CR62","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950\u2013961. https:\/\/doi.org\/10.1016\/S1470-2045(10)70204-7","journal-title":"Lancet Oncol"},{"key":"2199_CR63","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, Sun C-L, Landier W et al (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol 30:1415\u20131421. https:\/\/doi.org\/10.1200\/JCO.2011.34.8987","journal-title":"J Clin Oncol"},{"key":"2199_CR64","doi-asserted-by":"publisher","first-page":"C849","DOI":"10.1152\/ajpcell.00283.2008","volume":"295","author":"DP Jones","year":"2008","unstructured":"Jones DP (2008) Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 295:C849\u2013868. https:\/\/doi.org\/10.1152\/ajpcell.00283.2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"2199_CR65","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931\u2013947. https:\/\/doi.org\/10.1038\/nrd4002","journal-title":"Nat Rev Drug Discov"},{"key":"2199_CR66","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","volume":"20","author":"HJ Forman","year":"2021","unstructured":"Forman HJ, Zhang H (2021) Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov 20:689\u2013709. https:\/\/doi.org\/10.1038\/s41573-021-00233-1","journal-title":"Nat Rev Drug Discov"},{"key":"2199_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-017-2061-0","volume":"17","author":"T Afsar","year":"2017","unstructured":"Afsar T, Razak S, Batoo KM, Khan MR (2017) Acacia hydaspica R. parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural cardiomyocyte alterations in rats. BMC Complement Altern Med 17:554. https:\/\/doi.org\/10.1186\/s12906-017-2061-0","journal-title":"BMC Complement Altern Med"},{"key":"2199_CR68","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.3390\/ijms24087585","volume":"24","author":"A Zo\u0144","year":"2023","unstructured":"Zo\u0144 A, Bednarek I (2023) Cisplatin in ovarian cancer treatment\u2014known limitations in therapy force new solutions. IJMS 24:7585. https:\/\/doi.org\/10.3390\/ijms24087585","journal-title":"IJMS"},{"key":"2199_CR69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12012-022-09773-3","volume":"23","author":"C Yildirim","year":"2023","unstructured":"Yildirim C, Cangi S, Orkmez M et al (2023) Sinapic acid attenuated Cisplatin-induced cardiotoxicity by inhibiting oxidative stress and \u0130nflammation with GPX4-mediated NF-kB modulation. Cardiovasc Toxicol 23:10\u201322. https:\/\/doi.org\/10.1007\/s12012-022-09773-3","journal-title":"Cardiovasc Toxicol"},{"key":"2199_CR70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s13287-020-01984-1","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Li D, Sun F et al (2020) Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. Stem Cell Res Ther 11:470. https:\/\/doi.org\/10.1186\/s13287-020-01984-1","journal-title":"Stem Cell Res Ther"},{"key":"2199_CR71","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ymthe.2023.02.016","volume":"31","author":"A Zhang","year":"2023","unstructured":"Zhang A, Liu Y, Pan J et al (2023) Delivery of mitochondria confers cardioprotection through mitochondria replenishment and metabolic compliance. Mol Ther 31:1468\u20131479. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.016","journal-title":"Mol Ther"},{"key":"2199_CR72","doi-asserted-by":"crossref","unstructured":"D\u2019arcy MS (2019) Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 43(6):582\u2013592.","DOI":"10.1002\/cbin.11137"},{"key":"2199_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8641026","volume":"2020","author":"AY Al-Taher","year":"2020","unstructured":"Al-Taher AY, Morsy MA, Rifaai RA et al (2020) Paeonol attenuates methotrexate-induced cardiac toxicity in rats by inhibiting oxidative stress and suppressing TLR4-induced NF- \u03ba b inflammatory pathway. Mediators Inflamm 2020:1\u201310. https:\/\/doi.org\/10.1155\/2020\/8641026","journal-title":"Mediators Inflamm"},{"key":"2199_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/biom12020299","volume":"12","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Li Y, Zhang J et al (2022) RRM2 alleviates doxorubicin-induced cardiotoxicity through the AKT\/mTOR signaling pathway. Biomolecules 12:299. https:\/\/doi.org\/10.3390\/biom12020299","journal-title":"Biomolecules"},{"key":"2199_CR75","doi-asserted-by":"crossref","unstructured":"Bertheloot D, Latz E, Franklin BS (2021) Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol 18(5):1106\u20131121","DOI":"10.1038\/s41423-020-00630-3"},{"key":"2199_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.4017","volume":"22","author":"T Zhang","year":"2016","unstructured":"Zhang T, Zhang Y, Cui M et al (2016) CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress\u2013induced myocardial necroptosis. Nat Med 22:175\u2013182. https:\/\/doi.org\/10.1038\/nm.4017","journal-title":"Nat Med"},{"key":"2199_CR77","doi-asserted-by":"crossref","unstructured":"Burdette BE et al (2021) Gasdermin D in pyroptosis","DOI":"10.1016\/j.apsb.2021.02.006"},{"key":"2199_CR78","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41419-022-05333-3","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu Y, Gao R, Wei X et al (2022) Gasdermin D mediates endoplasmic reticulum stress via FAM134B to regulate cardiomyocyte autophagy and apoptosis in doxorubicin-induced cardiotoxicity. Cell Death Dis 13:901. https:\/\/doi.org\/10.1038\/s41419-022-05333-3","journal-title":"Cell Death Dis"},{"key":"2199_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim YC, Guan K-L (2015) mTOR: a pharmacologic target for autophagy regulation. J Clin Invest 125:25\u201332. https:\/\/doi.org\/10.1172\/JCI73939","journal-title":"J Clin Invest"},{"key":"2199_CR80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2478\/jtim-2023-0099","volume":"11","author":"J Li","year":"2023","unstructured":"Li J, Wang H (2023) Autophagy-dependent ferroptosis in infectious disease. J Transl Int Med 11:355\u2013362. https:\/\/doi.org\/10.2478\/jtim-2023-0099","journal-title":"J Transl Int Med"},{"key":"2199_CR81","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bcp.2014.01.040","volume":"88","author":"X Wang","year":"2014","unstructured":"Wang X, Wang X-L, Chen H-L et al (2014) Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol 88:334\u2013350. https:\/\/doi.org\/10.1016\/j.bcp.2014.01.040","journal-title":"Biochem Pharmacol"},{"key":"2199_CR82","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2014.01.002","volume":"71","author":"A Sun","year":"2014","unstructured":"Sun A, Cheng Y, Zhang Y et al (2014) Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy. J Mol Cell Cardiol 71:92\u2013104. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.01.002","journal-title":"J Mol Cell Cardiol"},{"key":"2199_CR83","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fcell.2020.00431","volume":"8","author":"Y Xie","year":"2020","unstructured":"Xie Y, Li J, Kang R, Tang D (2020) Interplay between lipid metabolism and autophagy. Front Cell Dev Biol 8:431. https:\/\/doi.org\/10.3389\/fcell.2020.00431","journal-title":"Front Cell Dev Biol"},{"key":"2199_CR84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2478\/jtim-2023-0137","volume":"12","author":"W Lai","year":"2024","unstructured":"Lai W, Wang B, Huang R et al (2024) Ferroptosis in organ fibrosis: from mechanisms to therapeutic medicines. J Transl Intern Med 12:22\u201334. https:\/\/doi.org\/10.2478\/jtim-2023-0137","journal-title":"J Transl Intern Med"},{"key":"2199_CR85","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang X, Wang H, Han D et al (2019) Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A 116:2672\u20132680. https:\/\/doi.org\/10.1073\/pnas.1821022116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2199_CR86","doi-asserted-by":"publisher","first-page":"e132747","DOI":"10.1172\/jci.insight.132747","volume":"5","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro T, Ikeda M, Ide T et al (2020) Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 5:e132747. https:\/\/doi.org\/10.1172\/jci.insight.132747","journal-title":"JCI Insight"},{"key":"2199_CR87","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q et al (2023) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther 8:207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1","journal-title":"Sig Transduct Target Ther"},{"key":"2199_CR88","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS\u2013) vs. alternatively activated macrophages. Front Immunol 10:1084. https:\/\/doi.org\/10.3389\/fimmu.2019.01084","journal-title":"Front Immunol"},{"key":"2199_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00514","author":"P Italiani","year":"2014","unstructured":"Italiani P, Boraschi D (2014) From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2014.00514","journal-title":"Front Immunol"},{"key":"2199_CR90","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00204-023-03586-1","volume":"97","author":"A Reis-Mendes","year":"2023","unstructured":"Reis-Mendes A, Ferreira M, Duarte JA et al (2023) The role of inflammation and antioxidant defenses in the cardiotoxicity of doxorubicin in elderly CD-1 male mice. Arch Toxicol 97:3163\u20133177. https:\/\/doi.org\/10.1007\/s00204-023-03586-1","journal-title":"Arch Toxicol"},{"key":"2199_CR91","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/cells8101224","volume":"8","author":"D Singla","year":"2019","unstructured":"Singla D, Johnson T, Tavakoli Dargani Z (2019) Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy. Cells 8:1224. https:\/\/doi.org\/10.3390\/cells8101224","journal-title":"Cells"},{"key":"2199_CR92","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.21037\/atm-21-3557","volume":"9","author":"D Shen","year":"2021","unstructured":"Shen D, He Z (2021) Mesenchymal stem cell-derived exosomes regulate the polarization and inflammatory response of macrophages via miR-21-5p to promote repair after myocardial reperfusion injury. Ann Transl Med 9:1323. https:\/\/doi.org\/10.21037\/atm-21-3557","journal-title":"Ann Transl Med"},{"key":"2199_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133290","volume":"15","author":"A Alexandraki","year":"2023","unstructured":"Alexandraki A, Papageorgiou E, Zacharia M et al (2023) New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers (Basel) 15:3290. https:\/\/doi.org\/10.3390\/cancers15133290","journal-title":"Cancers (Basel)"},{"key":"2199_CR94","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","volume":"13","author":"K Ananthan","year":"2020","unstructured":"Ananthan K, Lyon AR (2020) The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res 13:431\u2013450. https:\/\/doi.org\/10.1007\/s12265-020-10042-3","journal-title":"J Cardiovasc Transl Res"},{"key":"2199_CR95","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749\u20132754. https:\/\/doi.org\/10.1161\/01.CIR.0000130926.51766.CC","journal-title":"Circulation"},{"key":"2199_CR96","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4143\/crt.2008.40.3.121","volume":"40","author":"HS Lee","year":"2008","unstructured":"Lee HS, Son CB, Shin SH, Kim YS (2008) Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat 40:121\u2013126. https:\/\/doi.org\/10.4143\/crt.2008.40.3.121","journal-title":"Cancer Res Treat"},{"key":"2199_CR97","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.medcli.2020.04.024","volume":"155","author":"J Pedro-Botet","year":"2020","unstructured":"Pedro-Botet J, Climent E, Benaiges D (2020) Atherosclerosis and inflammation. New therapeutic approaches. Med Clin (Barc) 155:256\u2013262. https:\/\/doi.org\/10.1016\/j.medcli.2020.04.024","journal-title":"Med Clin (Barc)"},{"key":"2199_CR98","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436\u2013444. https:\/\/doi.org\/10.1038\/nature07205","journal-title":"Nature"},{"key":"2199_CR99","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.121.058411","volume":"146","author":"R Dhingra","year":"2022","unstructured":"Dhingra R, Rabinovich-Nikitin I, Rothman S et al (2022) Proteasomal degradation of TRAF2 mediates mitochondrial dysfunction in doxorubicin-cardiomyopathy. Circulation 146:934\u2013954. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058411","journal-title":"Circulation"},{"key":"2199_CR100","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/jvim.15762","volume":"34","author":"A Beaumier","year":"2020","unstructured":"Beaumier A, Robinson SR, Robinson N et al (2020) Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity. J Vet Intern Med 34:1260\u20131271. https:\/\/doi.org\/10.1111\/jvim.15762","journal-title":"J Vet Intern Med"},{"key":"2199_CR101","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-17-2046","volume":"24","author":"C Yarana","year":"2018","unstructured":"Yarana C, Carroll D, Chen J et al (2018) Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury. Clin Cancer Res 24:1644\u20131653. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2046","journal-title":"Clin Cancer Res"},{"key":"2199_CR102","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1373\/clinchem.2016.264648","volume":"63","author":"J Marjot","year":"2017","unstructured":"Marjot J, Kaier TE, Martin ED et al (2017) Quantifying the release of biomarkers of myocardial necrosis from cardiac myocytes and intact myocardium. Clin Chem 63:990\u2013996. https:\/\/doi.org\/10.1373\/clinchem.2016.264648","journal-title":"Clin Chem"},{"key":"2199_CR103","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 72:2231\u20132264. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038","journal-title":"J Am Coll Cardiol"},{"key":"2199_CR104","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.1.4.715","author":"DC Gaze","year":"2005","unstructured":"Gaze DC, Collinson PO (2005) Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opin Drug Metab Toxicol. https:\/\/doi.org\/10.1517\/17425255.1.4.715","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2199_CR105","unstructured":"Michel L, Mincu RI, Mrotzek SM et al Cardiac biomarkers for the detection of cardiotoxicity in childhood cancera meta-analysis. ESC Heart Fail"},{"key":"2199_CR106","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R et al (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international cardiooncology Society-one trial. Eur J Cancer 94:126\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005","journal-title":"Eur J Cancer"},{"key":"2199_CR107","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"2199_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107863","volume":"227","author":"K Kuwahara","year":"2021","unstructured":"Kuwahara K (2021) The natriuretic peptide system in heart failure: diagnostic and therapeutic implications. Pharmacol Ther 227:107863. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107863","journal-title":"Pharmacol Ther"},{"key":"2199_CR109","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.025935","volume":"11","author":"JM Leerink","year":"2022","unstructured":"Leerink JM, Feijen EAM, Moerland PD et al (2022) Candidate plasma biomarkers to detect anthracycline-related cardiomyopathy in childhood cancer survivors: a case control study in the Dutch Childhood Cancer Survivor Study. J Am Heart Assoc 11:e025935. https:\/\/doi.org\/10.1161\/JAHA.121.025935","journal-title":"J Am Heart Assoc"},{"key":"2199_CR110","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/1097-0142(19920315)69:6<1492::AID-CNCR2820690630>3.0.CO;2-3","volume":"69","author":"M Bauch","year":"1992","unstructured":"Bauch M, Ester A, Kimura B et al (1992) Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 69:1492\u20131497","journal-title":"Cancer"},{"key":"2199_CR111","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.3892\/ol.2019.10827","volume":"18","author":"X Lu","year":"2019","unstructured":"Lu X, Zhao Y, Chen C et al (2019) BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer. Oncol Lett 18:4992\u20135001. https:\/\/doi.org\/10.3892\/ol.2019.10827","journal-title":"Oncol Lett"},{"key":"2199_CR112","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","volume":"30","author":"SE Lipshultz","year":"2012","unstructured":"Lipshultz SE, Miller TL, Scully RE et al (2012) Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 30:1042\u20131049. https:\/\/doi.org\/10.1200\/JCO.2010.30.3404","journal-title":"J Clin Oncol"},{"key":"2199_CR113","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2011.439","volume":"105","author":"S Romano","year":"2011","unstructured":"Romano S, Fratini S, Ricevuto E et al (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105:1663\u20131668. https:\/\/doi.org\/10.1038\/bjc.2011.439","journal-title":"Br J Cancer"},{"key":"2199_CR114","first-page":"1197","volume":"26","author":"M Soker","year":"2005","unstructured":"Soker M, Kervancioglu M (2005) Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 26:1197\u20131202","journal-title":"Saudi Med J"},{"key":"2199_CR115","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/hj.1998.v136.89908","volume":"136","author":"T Suzuki","year":"1998","unstructured":"Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362\u2013363. https:\/\/doi.org\/10.1053\/hj.1998.v136.89908","journal-title":"Am Heart J"},{"key":"2199_CR116","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1159\/000507585","volume":"98","author":"M Oikawa","year":"2020","unstructured":"Oikawa M, Yoshihisa A, Yokokawa T et al (2020) Cardiac troponin I predicts elevated B-type natriuretic peptide in patients treated with anthracycline-containing chemotherapy. Oncology 98:653\u2013660. https:\/\/doi.org\/10.1159\/000507585","journal-title":"Oncology"},{"key":"2199_CR117","first-page":"340","volume":"125","author":"A Oren","year":"1995","unstructured":"Oren A, Taylor JM (1995) The subcellular localization of defensins and myeloperoxidase in human neutrophils: immunocytochemical evidence for azurophil granule heterogeneity. J Lab Clin Med 125:340\u2013347","journal-title":"J Lab Clin Med"},{"key":"2199_CR118","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63:809\u2013816. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061","journal-title":"J Am Coll Cardiol"},{"key":"2199_CR119","doi-asserted-by":"publisher","first-page":"214","DOI":"10.18632\/oncotarget.28182","volume":"13","author":"MR Wanderley","year":"2022","unstructured":"Wanderley MR, de B, \u00c1vila MS, Fernandes-Silva MM et al (2022) Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY trial. Oncotarget 13:214\u2013223. https:\/\/doi.org\/10.18632\/oncotarget.28182","journal-title":"Oncotarget"},{"key":"2199_CR120","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/biom12121788","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Gao D, Xue J, Zuo Z (2022) Galectin-3 and myeloperoxidase may monitor cancer-therapy-related cardiotoxicity? A systematic review and meta-analysis. Biomolecules 12:1788. https:\/\/doi.org\/10.3390\/biom12121788","journal-title":"Biomolecules"},{"key":"2199_CR121","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","volume":"72","author":"A Shimabukuro-Vornhagen","year":"2022","unstructured":"Shimabukuro-Vornhagen A, B\u00f6ll B, Schellongowski P et al (2022) Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin 72:78\u201393. https:\/\/doi.org\/10.3322\/caac.21702","journal-title":"CA Cancer J Clin"},{"key":"2199_CR122","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","volume":"22","author":"J Hartman","year":"2014","unstructured":"Hartman J, Frishman WH (2014) Inflammation and atherosclerosis: a review of the role of Interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 22:147\u2013151. https:\/\/doi.org\/10.1097\/CRD.0000000000000021","journal-title":"Cardiol Rev"},{"key":"2199_CR123","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1254\/jjp.88.183","volume":"88","author":"K Okumura","year":"2002","unstructured":"Okumura K, Jin D, Takai S, Miyazaki M (2002) Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 88:183\u2013188. https:\/\/doi.org\/10.1254\/jjp.88.183","journal-title":"Jpn J Pharmacol"},{"key":"2199_CR124","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474\u20132481. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144","journal-title":"Circulation"},{"key":"2199_CR125","first-page":"37","volume":"25","author":"HS Hochster","year":"1998","unstructured":"Hochster HS (1998) Clinical pharmacology of Dexrazoxane. Semin Oncol 25:37\u201342","journal-title":"Semin Oncol"},{"key":"2199_CR126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035153","author":"SE Lipshultz","year":"2004","unstructured":"Lipshultz SE, Levy DE, Colan SD et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa035153","journal-title":"N Engl J Med"},{"key":"2199_CR127","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. https:\/\/doi.org\/10.1186\/1471-2407-10-337","journal-title":"BMC Cancer"},{"key":"2199_CR128","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s002800100348","volume":"48","author":"EH Herman","year":"2001","unstructured":"Herman EH, Zhang J, Rifai N et al (2001) The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48:297\u2013304. https:\/\/doi.org\/10.1007\/s002800100348","journal-title":"Cancer Chemother Pharmacol"},{"key":"2199_CR129","doi-asserted-by":"crossref","unstructured":"Park KM, Teoh JP, Wang Y, Broskova Z, Bayoumi AS, Tang Y, Su H, Weintraub NL, Kim IM (2016) Carvedilol-responsive microRNAs, miR-199a-3p and-214 protect cardiomyocytes from simulated ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 311(2):H371\u2013H383","DOI":"10.1152\/ajpheart.00807.2015"},{"key":"2199_CR130","doi-asserted-by":"crossref","unstructured":"Bayoumi AS, Park K, Wang Y et al (2019) A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes","DOI":"10.1016\/j.yjmcc.2017.11.003"},{"key":"2199_CR131","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3892\/mmr.2019.10034","volume":"19","author":"Y Hu","year":"2019","unstructured":"Hu Y, Chen X, Li X et al (2019) MicroRNA\u20131 downregulation induced by carvedilol protects cardiomyocytes against apoptosis by targeting heat shock protein 60. Mol Med Rep 19:3527\u20133536. https:\/\/doi.org\/10.3892\/mmr.2019.10034","journal-title":"Mol Med Rep"},{"key":"2199_CR132","unstructured":"Avila MS (2018) Carvedilol for prevention of chemotherapy related cardiotoxicity"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02199-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02199-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02199-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:33:43Z","timestamp":1773999223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02199-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02199-6","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"16"}}